Portal de Periódicos da CAPES

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

2009; Massachusetts Medical Society; Volume: 361; Issue: 10 Linguagem: Inglês

10.1056/nejmoa0904554

1533-4406

Rafael Rosell, Teresa Morán, Cristina Queralt, Rut Porta, Enriqueta Felip, Carlos Camps, Margarita Majem, Guillermo López-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massutí, J.L. González-Larriba, Luis Paz‐Ares, Isabel Bover, Rosario Garcίa‐Campelo, Miguel Ángel Moreno, Sílvia Catot, Christian Rolfo, Noemı́ Reguart, Ramón Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Ángel Molina‐Vila, José Javier Sánchez, Miquel Tarón,

Colorectal Cancer Treatments and Studies

Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non–small-cell lung cancer. We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment.